Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 19Gastrointestinal 17Lymphoid 8Gynecologic 6Breast 5Genitourinary 3Other hematologic neoplasm 2Head & Neck 2Dermatologic 2Classical hematology 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Other 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Folic Acid × Tumor-Agnostic × Clear all
NCT00034463 2006-07-19

ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡